AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
In the second replicate study (Study 1) of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 45.2% and 55.0% of patients with severe alopecia areata treated with upadacitinib 15 mg and 30 mg, respectively, reached 80% or...
Related Questions
How will the positive Phase 3 results for upadacitinib in alopecia areata affect AbbVie's short‑term stock momentum and price target?
What is the expected timeline for FDA submission and potential approval for the alopecia areata indication, and how might that compare to competitors' pipelines?
What are the projected market size and revenue opportunity for upadacitinib in alopecia areata, and how will pricing, reimbursement, and off‑label use influence AbbVie's long‑term earnings outlook?